BioInformant

Your Global Leader in Stem Cell Market Research

Nano-race: Industrial Landscape of Exosome-Based Therapeutics and Diagnostics

By 2 Comments

Exosomes are nano-sized vesicles ranging from 30-200nm that are present in eukaryotic fluids and facilitate a diverse range of cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.

Because of their far ranging potential, exosomes can be commercialized as therapeutic agents, diagnostic tools, and cosmeceuticals. Today, a surging number of companies are developing exosome-based products and technologies.

Exosome Market Competitors

Currently, there are at least 45 market competitors which compose the exosome industry in therapeutics and diagnostics. Twenty six of them are companies specializing in exosomes and nineteen of them are established companies that have recently jumped into the exosome industry.
[Read more…]

Editas Medicine Granted RMAT Designation for EDIT-301 for Severe Sickle Cell Disease

By Leave a Comment

October 17, 2023, CAMBRIDGE, Mass. — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD). [Read more…]

Stem Cell Therapy: A New Treatment Approach In Multiple Sclerosis

By 1 Comment

Multiple sclerosis (MS) is a neurodegenerative disease with symptoms associated with impaired conduction of nerve fibers. The disease has an autoimmune nature with the own immune system attacking the myelin sheath.

Unlike other common diseases of the nervous system (dementia, Alzheimer’s disease, Parkinson’s disease) MS is not considered age-related. Multiple sclerosis affects middle-aged people, both women and men, though more often the latter. [Read more…]

Bayer to Advance Cell Therapy Manufacturing with $250M, All-Electric Facility

By Leave a Comment

  • $250 million (USD) plant will help produce transformational cell and gene therapies on a global scale
  • Creating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply for late-stage clinical trials
  • New plant helps break industry-wide bottleneck in manufacturing capacity for regenerative medicines
  • 100,000 sq. ft. building advances Bayer’s sustainability efforts – first fully electric manufacturing plant in Bayer’s global pharmaceutical manufacturing network

[Read more…]

Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology

By Leave a Comment

SINGAPORE — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA). [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0